20/20 Biolabs reports Q1 GAAP EPS of -$0.28 and revenue of $0.35M, both below expectations.
20/20 Biolabs, Inc. (AIDX) reported a Q1 GAAP loss per share of $0.28, missing estimates by $0.18. Revenue declined 36.4% year-over-year to $0.35 million, falling short of expectations by $0.43 million.
The company’s cash position improved to $4.2 million as of March 31, 2026, up from $1.0 million at the end of 2025, driven by recent capital raises. Analysts had anticipated stronger performance amid ongoing operational challenges.
Shares may face pressure as investors assess the weaker-than-expected results and revenue contraction.